XORTX Therapeutics Receives 180-Day Extension to Regain Nasdaq Compliance

XORTX Therapeutics Inc. announced that it received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The company was initially notified of non-compliance on April 17, 2025, and was given until October 14, 2025, to meet the requirement. With the extension, XORTX now has until April 13, 2026, to achieve compliance. If the company fails to meet the requirement by the new deadline, its common shares may be delisted. XORTX is also listed on the TSX Venture Exchange, and the Nasdaq notification does not affect its compliance status there. The company is evaluating all available options to resolve the deficiency and regain compliance. XORTX is a pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other conditions.